23 citations
,
April 2018 in “PubMed” This review finds preliminary evidence suggesting that topical finasteride may significantly reduce hair loss and increase hair counts in treating androgenetic alopecia, with a promising safety profile.
14 citations
,
February 2018 in “Psychoneuroendocrinology” This study found that male 5α-reductase 2 knockout mice showed deficits in social dominance behaviors and reduced dopamine receptor binding in a brain region related to social ranking.
178 citations
,
April 2017 in “Journal of The American Academy of Dermatology” This systematic review and meta-analysis found that minoxidil, finasteride, and low-level laser light therapy significantly improve hair growth in men with androgenetic alopecia, while minoxidil is also effective for women, compared to placebo.
8 citations
,
March 2017 in “Journal of Mind and Medical Sciences” This article discusses the theoretical perspective of the informational dichotomy of the mind in relation to sexuality and presents no new empirical results; further theoretical exploration is planned.
27 citations
,
March 2017 in “Current Clinical Pharmacology” In this review, the authors discuss the pharmacology of dutasteride and compare its efficacy to finasteride for treating androgenetic alopecia, highlighting dutasteride's effectiveness demonstrated in several clinical trials.
31 citations
,
January 2017 in “Advances in Experimental Medicine and Biology” This review discusses the negative health impacts of testosterone deficiency and the potential adverse effects of 5α-reductase inhibitors, emphasizing the need for patient-physician discussions regarding these treatments.
9 citations
,
January 2017 in “Farmacia” This review discusses the safety of finasteride for male androgenic alopecia and benign prostatic hyperplasia, concluding it remains a viable option due to synergistic effects with other treatments and predictive measures for side effect risk.
48 citations
,
January 2017 in “International Journal of Trichology” This study found that combining microneedling with PRP and topical minoxidil (5%) significantly improved hair growth in men with androgenetic alopecia compared to using minoxidil alone.
6 citations
,
September 2016 in “Journal of Mind and Medical Sciences” This article reviews finasteride's potential side effects, notably post-finasteride syndrome, and suggests that hand preference and sexual orientation might predict these adverse effects, but it reports no clinical results.
50 citations
,
September 2016 in “The Journal of Clinical Endocrinology and Metabolism” This study found no evidence of androgen deficiency or decreased peripheral androgen action in men with persistent sexual symptoms after finasteride use, but identified links to depressed mood and abnormal brain function.
21 citations
,
April 2016 in “Journal of Dermatological Treatment” This paper discusses the potential relationship between finasteride's adverse effects and factors like hand preference and sexual orientation, suggesting these could influence risk in male androgenic alopecia treatment, but reports no new clinical results.
5 citations
,
November 2015 in “Journal of Mind and Medical Sciences” This review discusses the adverse effects of finasteride for male androgenic alopecia, highlighting depressive symptoms and persistent sexual dysfunction, and reports no new clinical findings.
29 citations
,
November 2012 in “Journal of The European Academy of Dermatology and Venereology” This review discusses the development of an algorithmic guideline for treating androgenetic alopecia in Asian patients, using the BASP classification to address limitations of previous guidelines, and reports no clinical results.
7 citations
,
January 2011 in “Journal of The American Academy of Dermatology” This study observed that moderate to severe acne is the most common manifestation in women with hyperandrogenism and highlights acanthosis nigricans and hirsutism as useful clinical markers.
12 citations
,
January 2010 in “PubMed” This article summarizes the MHRA report on finasteride and does not present new clinical findings.
47 citations
,
June 2009 in “Journal of Biological Chemistry” This study found that finasteride competitively inhibits the enzyme AKR1D1 with low micromolar affinity but does not act as a mechanism-based inactivator.
225 citations
,
July 2007 in “The Journal of Sexual Medicine” In this study, patients informed about finasteride's potential sexual side effects reported a significantly higher occurrence of these side effects, suggesting a nocebo effect.